Georgios Giamas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4510460/publications.pdf

Version: 2024-02-01

93 papers	2,794 citations	186265 28 h-index	189892 50 g-index
96 all docs	96 docs citations	96 times ranked	5133 citing authors

#	Article	IF	Citations
1	Cancer gene therapy 2020: highlights from a challenging year. Cancer Gene Therapy, 2022, 29, 1-3.	4.6	4
2	Diving into the dark kinome: lessons learned from LMTK3. Cancer Gene Therapy, 2022, 29, 1077-1079.	4.6	3
3	Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment. Biomolecules, 2022, 12, 132.	4.0	7
4	Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients. Biomedicines, 2022, 10, 125.	3.2	10
5	Tuneable synthetic reduced graphene oxide scaffolds elicit high levels of three-dimensional glioblastoma interconnectivity in vitro. Journal of Materials Chemistry B, 2022, 10, 373-383.	5.8	4
6	Alternative splicing events in tumor immune infiltration in renal clear cell carcinomas. Cancer Gene Therapy, 2022, 29, 1418-1428.	4.6	2
7	PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38MAPK signalling. Oncogene, 2022, 41, 2749-2763.	5.9	14
8	The LMTK-family of kinases: Emerging important players in cell physiology and pathogenesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 165372.	3.8	15
9	The role of astrocytes in brain metastasis at the interface of circulating tumour cells and the blood brain barrier. Frontiers in Bioscience, 2021, 26, 590.	2.1	9
10	LMTK3 inhibition affects microtubule stability. Molecular Cancer, 2021, 20, 53.	19.2	6
11	Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. Science Translational Medicine, 2021, 13, .	12.4	19
12	The multifaceted role of lemur tyrosine kinase 3 in health and disease. Open Biology, 2021, 11, 210218.	3.6	4
13	Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth. Hepatology, 2021, 74, 2561-2579.	7.3	13
14	A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers. Frontiers in Immunology, 2021, 12, 762598.	4.8	39
15	Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. International Journal of Molecular Sciences, 2021, 22, 12015.	4.1	9
16	A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 778637.	2.8	2
17	The structure-function relationship of oncogenic LMTK3. Science Advances, 2020, 6, .	10.3	18
18	Langmuir Films of Layered Nanomaterials: Edge Interactions and Cell Culture Applications. Journal of Physical Chemistry B, 2020, 124, 7184-7193.	2.6	2

#	Article	IF	Citations
19	Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing. Oncogene, 2020, 39, 6172-6189.	5.9	23
20	Three Method-Combination Protocol for Improving Purity of Extracellular Vesicles. International Journal of Molecular Sciences, 2020, 21, 3071.	4.1	11
21	Breaking through the glioblastoma micro-environment via extracellular vesicles. Oncogene, 2020, 39, 4477-4490.	5.9	72
22	Reviewer Recognition. Cancer Gene Therapy, 2020, 27, 264-264.	4.6	0
23	Cancer Gene Therapy: vision and strategy for the new decade. Cancer Gene Therapy, 2020, 27, 115-115.	4.6	7
24	Graphene-Induced Transdifferentiation of Cancer Stem Cells as a Therapeutic Strategy against Glioblastoma. ACS Biomaterials Science and Engineering, 2020, 6, 3258-3269.	5.2	9
25	PIK3CÎ´ expression by fibroblasts promotes triple-negative breast cancer progression. Journal of Clinical Investigation, 2020, 130, 3188-3204.	8.2	33
26	Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping. Communications Biology, 2019, 2, 315.	4.4	71
27	Evaluation of Spheroid 3D Culture Methods to Study a Pancreatic Neuroendocrine Neoplasm Cell Line. Frontiers in Endocrinology, 2019, 10, 682.	3.5	52
28	Endocrine Resistance in Hormone Receptor Positive Breast Cancerâ€“From Mechanism to Therapy. Frontiers in Endocrinology, 2019, 10, 245.	3.5	150
29	Astrocytes, the rising stars of the glioblastoma microenvironment. Glia, 2019, 67, 779-790.	4.9	115
30	EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR?. Endocrine Connections, 2019, 8, 680-690.	1.9	6
31	LMTK3 confers chemo-resistance in breast cancer. Oncogene, 2018, 37, 3113-3130.	5.9	31
32	Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma. Molecular Cancer, 2018, 17, 132.	19.2	67
33	Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling. Trends in Molecular Medicine, 2017, 23, 282-292.	6.7	70
34	Extracellular vesicles swarm the cancer microenvironment: from tumorâ€“stroma communication to drug intervention. Oncogene, 2017, 36, 877-884.	5.9	117
35	Proteome-wide dataset supporting functional study of tyrosine kinases in breast cancer. Data in Brief, 2016, 7, 740-746.	1.0	3
36	Advances in integrative statistics for logic programming. International Journal of Approximate Reasoning, 2016, 78, 103-115.	3.3	2

#	Article	IF	Citations
37	Tumorâ€“Stromal Cell Communication: Small Vesicles Signal Big Changes. Trends in Cancer, 2016, 2, 326-329.	7.4	28
38	Reply: When does a human being die?. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 146-146.	0.5	0
39	Strategies in functional proteomics: Unveiling the pathways to precision oncology. Cancer Letters, 2016, 382, 86-94.	7.2	7
40	LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5. Cancer Letters, 2016, 372, 137-146.	7.2	30
41	Targeting tumorâ€“stroma crosstalk: the example of the NT157 inhibitor. Oncogene, 2016, 35, 2562-2564.	5.9	7
42	ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation. Oncotarget, 2016, 7, 27599-27612.	1.8	21
43	miRNA transported by exosomes: a key machinery in tumor microenvironment mediated chemoresistance. Translational Cancer Research, 2016, 5, S1479-S1482.	1.0	3
44	mTOR inhibition in breast cancer. Breast Cancer Management, 2015, 4, 67-70.	0.2	0
45	When does a human being die?. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 605-609.	0.5	18
46	LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer. Cell Reports, 2015, 12, 837-849.	6.4	21
47	Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics. Molecular and Cellular Proteomics, 2015, 14, 2479-2492.	3.8	17
48	Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer. Breast Cancer Research and Treatment, 2015, 151, 555-568.	2.5	10
49	Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERÎ±-positive advanced breast cancer. Pharmacogenomics Journal, 2015, 15, 235-240.	2.0	2
50	KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. Oncogene, 2015, 34, 2103-2114.	5.9	17
51	The many-faced KSR1: a tumor suppressor in breast cancer. Oncoscience, 2015, 2, 669-670.	2.2	0
52	The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated Induction of Integrin Î² ₁. Science Signaling, 2014, 7, ra58.	3.6	32
53	Broader implications of SILAC-based proteomics for dissecting signaling dynamics in cancer. Expert Review of Proteomics, 2014, 11, 713-731.	3.0	5
54	Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. Pharmacogenomics Journal, 2014, 14, 28-34.	2.0	29

#	Article	IF	Citations
55	The regulatory roles of phosphatases in cancer. Oncogene, 2014, 33, 939-953.	5.9	89
56	MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma. PLoS ONE, 2014, 9, e85935.	2.5	26
57	Targeting lemurs against cancer metastasis. Oncotarget, 2014, 5, 5192-5193.	1.8	4
58	Cancer stem cellsâ€"therapeutic targeting or therapy?. Lancet Oncology, The, 2013, 14, 579-580.	10.7	3
59	Claudin-1 as a promoter of EMT in hepatocellular carcinoma. Oncogene, 2013, 32, 4871-4872.	5.9	44
60	SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1. British Journal of Cancer, 2013, 109, 2675-2684.	6.4	16
61	The dual function of KSR1: a pseudokinase and beyond. Biochemical Society Transactions, 2013, 41, 1078-1082.	3.4	37
62	Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States. Molecular Cancer Therapeutics, 2013, 12, 2261-2272.	4.1	19
63	LMTK3 is implicated in endocrine resistance via multiple signaling pathways. Oncogene, 2013, 32, 3371-3380.	5.9	40
64	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of breast cancer management. Breast Cancer Management, 2013, 2, 455-457.	0.2	0
65	LATS2 is a modulator of estrogen receptor alpha. Anticancer Research, 2013, 33, 53-63.	1.1	19
66	Breast cancer and LMTK3: old disease, new target. Breast Cancer Management, 2012, 1, 101-103.	0.2	0
67	Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16558-16563.	7.1	71
68	MicroRNAs Targeting Oncogenes Are Down-Regulated in Pancreatic Malignant Transformation from Benign Tumors. PLoS ONE, 2012, 7, e32068.	2.5	122
69	LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Research and Treatment, 2012, 132, 537-544.	2.5	35
70	The role of pseudokinases in cancer. Cellular Signalling, 2012, 24, 1173-1184.	3.6	32
71	LMTK3 polymorphism in patients with metastatic colon cancer.. Journal of Clinical Oncology, 2012, 30, 471-471.	1.6	6
72	Use of genetic variants of LMTK3 to predict tumor recurrence in female localized gastric adenocarcinoma.. Journal of Clinical Oncology, 2012, 30, 63-63.	1.6	1

#	Article	IF	Citations
73	Association of gender-related tumor recurrence with a polymorphic variant of LMTK3 in stage II and III colon cancer.. Journal of Clinical Oncology, 2012, 30, 454-454.	1.6	3
74	Genetic variants of kinases suppressors of ras in KRAS-BRAF wild-type metastatic colorectal cancer patients treated with cetuximab and irinotecan.. Journal of Clinical Oncology, 2012, 30, 3597-3597.	1.6	0
75	Genetic variants of kinases suppressors of ras (KSR1) to predict survival in patients with ER-alpha positive metastatic breast cancer.. Journal of Clinical Oncology, 2012, 30, e11018-e11018.	1.6	0
76	Prognostic value of lemur tyrosine kinase-3 (LMTK3) polymorphism in Japanese (J) patients (PTS) with localized gastric adenocarcinoma (GAC).. Journal of Clinical Oncology, 2012, 30, 4088-4088.	1.6	0
77	KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab.. Journal of Clinical Oncology, 2012, 30, 3546-3546.	1.6	0
78	Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nature Medicine, 2011, 17, 715-719.	30.7	118
79	The potential role of cyclooxygenase-2 (COX-2) during early breast cancer therapy. Annals of Oncology, 2011, 22, 1700-1702.	1.2	2
80	Lemur tyrosine kinase-3 (LMTK3) in cancer and evolution. Oncotarget, 2011, 2, 428-429.	1.8	12
81	Kinases as targets in the treatment of solid tumors. Cellular Signalling, 2010, 22, 984-1002.	3.6	88
82	Abstract LB-226: Identification of novel kinases modulating ER: new therapeutic targets in breast cancer. , 2010, , .		0
83	CK1Î´ modulates the transcriptional activity of ERÎ± via AIB1 in an estrogen-dependent manner and regulates ERÎ±â€“AIB1 interactions. Nucleic Acids Research, 2009, 37, 3110-3123.	14.5	27
84	The estrogen receptor-Î±-induced microRNA signature regulates itself and its transcriptional response. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15732-15737.	7.1	306
85	The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. Cancer, 2008, 113, 1489-1495.	4.1	14
86	Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo. Gut, 2008, 57, 799-806.	12.1	91
87	Bendamustine as a model for the activity of alkylating agents. Future Oncology, 2008, 4, 323-332.	2.4	7
88	Clinical significance of circulating tumor cells. Biomarkers in Medicine, 2007, 1, 341-342.	1.4	2
89	Phosphorylation of CK1Î´: identification of Ser370 as the major phosphorylation site targeted by PKA in vitro and in vivo. Biochemical Journal, 2007, 406, 389-398.	3.7	64
90	Protein kinases as targets for cancer treatment. Pharmacogenomics, 2007, 8, 1005-1016.	1.3	68

#	Article	IF	Citations
91	Phosphorylation at Ser244 by CK1 determines nuclear localization and substrate targeting of PKD2. EMBO Journal, 2007, 26, 4619-4633.	7.8	47
92	Casein kinase 1 delta (CK1Î´) interacts with the SNARE associated protein snapin. FEBS Letters, 2006, 580, 6477-6484.	2.8	27
93	The Role of the Casein Kinase 1 (CK1) Family in Different Signaling Pathways Linked to Cancer Development. Oncology Research and Treatment, 2005, 28, 508-514.	1.2	86